One sign of the coming of a new year in the biotechnology sector is the annual release of Steven Burrill’s Biotech Outlook, which augurs the world of biotechnology for the upcoming year. BioCommerce Week caught up with Burrill, the CEO of San Francisco-based private equity firm Burrill & Co., which manages some $500 million in investment funds, to look at the emerging systems biology marketplace.

What is your outlook for ‘05?

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.